Evidence map›Paper›PMID 31074817›Full record

ArticleJAMA network open2019

Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan.

Jagpreet Chhatwal, Qiushi Chen, Xiaojie Wang, Turgay Ayer, Yueran Zhuo, Naveed Z Janjua, Fasiha Kanwal

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Genomic Relevance ofJournal of clinical medicine · 2022
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2020
    Article
  15. State of the Hepatitis C Virus Care Cascade.Clinical liver disease · 2020
    Review
  16. Article
  17. Article
  18. Article
  19. The 8Canadian liver journal · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

Jagpreet ChhatwalHarvard Medical School, Boston, Massachusetts.
Qiushi ChenHarvard Medical School, Boston, Massachusetts.
Xiaojie WangDepartment of Industrial and Systems Engineering, University of Florida, Gainesville.
Turgay AyerH. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta.
Yueran ZhuoMassachusetts General Hospital Institute for Technology Assessment, Boston.
Naveed Z JanjuaBritish Columbia Centre for Disease Control, Vancouver, British Columbia, Canada.
Fasiha KanwalHouston Veterans Affairs Health Services Research and Development Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.
Massachusetts General Hospital · USCenter for Assessment · USGeorgia Institute of Technology · USMichael E. DeBakey VA Medical Center · USUniversity of British Columbia · CAUniversity of Florida · US

Funding

Tissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI James Versalovic · 2001 to 2026
$28.3M
NIDDK NIH HHS P30 DK056338
6 · The paper itself

Abstract

Importance: Chronic hepatitis C virus (HCV) infection is a global health problem. The World Health Assembly recently pledged to eliminate HCV by 2030. However, in Pakistan, a country with one of the highest prevalence rates, the feasibility and cost of HCV elimination are not known. Objectives: To investigate whether and under what conditions HCV elimination is feasible in Pakistan and to estimate the cost of such elimination. Design, Setting, and Participants: This decision analytical model study used a microsimulation model of the HCV epidemic in Pakistan from 2015 to 2030. Using Pakistan-specific variables, the model simulated the landscape of HCV in Pakistan and evaluated the minimum required screening and treatment rates needed to eliminate HCV in Pakistan. The study used simulated individuals chronically infected with HCV from 2015 to 2030. The analysis was performed in 2018. Interventions: The status quo and 7 scenarios that can lead to HCV elimination in Pakistan by 2030, which were defined by different combinations of tests for screening, detection of viremia before treatment, and confirmation of treatment response. Main Outcomes and Measures: Temporal trends in HCV infection prevalence, mortality, and disability-adjusted life-years and total cost of HCV infection care under the status quo and scenarios that can eliminate HCV by 2030. Results: Under the status quo, from 2015 to 2030, 1.44 million people are projected to die of HCV infection; 48% of deaths would be among people younger than 50 years. To achieve HCV elimination in Pakistan, HCV testing would need to be scaled up to at least 25 million people to diagnose 900 000 persons and treatment to 700 000 people per year. Compared with the status quo, the elimination scenario would avert 323 000 liver-related deaths and 13.0 million HCV-associated disability-adjusted life-years from 2015 to 2030. The elimination scenario was associated with cost savings of $2.6 billion from 2018 to 2030 with use of a point-of-care test for population-wide antibody screening and detection of viremia and treatment response. Conclusions and Relevance: Substantial scale-up of HCV testing and treatment may be essential to eliminate HCV infection in Pakistan, and such a strategy may be associated with cost savings in the near future. Although HCV elimination in Pakistan may be ambitious, strategic planning and strong support from the government may aid in its elimination.

Indexed as

Cost-Benefit AnalysisCost of IllnessFeasibility StudiesHepatitis CHumansMass ScreeningModels, TheoreticalPakistan

Identifiers

PMID31074817
PMCPMC6512462
OpenAlexW2944579628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.